ERBB2 and breast cancer: The combination of CDK4/6i with endocrine therapy has significantly improved progression-free survival (PFS) and overall survival (OS) in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.